Clinical Data 23andMe study explains variable results with obesity drugs PharmaphorumGene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.Clinical DataMetabolic & GLP-1Read full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: EverSea Medicines to acquire Hasten BiopharmaceuticalsNext: The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
